Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius Oncology (Nasdaq: CTOR), today announced significant progress in preparations ...

"I’m more just mad at myself for getting too caught up in the record and not caught up enough in the sprint finish," the ...

D. Boral Capital upgraded Citius Pharmaceuticals (CTXR) to Buy from Hold with a $9 price target. Citius owns 90% of Citius Oncology (CTOR), which is close to commercializing Lymphir, an ...

In a report released yesterday, Michael Okunewitch from Maxim Group maintained a Buy rating on Citius Oncology (CTOR – Research Report), with a ...

Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the ...

“For the second consecutive year, Weini Kelati improved on the American record at the Houston Half Marathon,“ Runner’s World ...

D. Boral Capital reiterated their buy rating on shares of Citius Pharmaceuticals (NASDAQ:CTXR – Free Report) in a report released on Tuesday morning,Benzinga reports. D. Boral Capital currently has a ...

On Monday, Boral (OTC:BOALY) Capital raised its rating on Citius Pharmaceuticals (NASDAQ: NASDAQ:CTXR) shares from Hold to Buy, setting a price target of $9.00. The upgrade reflects an adjustment ...

Walgreens Boots leads the week’s big gainers, while Edison International and Palantir slide. We sell different types of products and services to both investment professionals and individual ...

Citius Pharma ( (CTXR)) has released its Q4 earnings. Here is a breakdown of the information Citius Pharma presented to its investors. Citius Pharmaceuticals, Inc. is a biopharmaceutical company ...

Citius Pharmaceuticals shares are trading lower by 15% during Wednesday's session. The company announced a $3 million registered direct offering. The company will issue 743,496 shares of common ...